Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations
May 27 2020 - 9:00AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Jay Ramsinghani has joined the company as Vice President of
Commercial Strategy and Operations. In this new role, Mr.
Ramsinghani will be responsible for Arcutis’ commercial operations
efforts as the Company prepares for the potential future
commercialization of its product candidates.
“Jay is a highly accomplished commercial
operations executive with over 18 years of biopharmaceutical
industry and consulting experience, much of which have been
specifically focused on the dermatology market,” said Ken Lock,
Arcutis’ Chief Commercial Officer. “Jay’s previous success in
building sales and marketing operations functions from the ground
up will be instrumental as we transform Arcutis from a research and
development organization into a fully-integrated commercial
dermatology company.”
Prior to joining Arcutis, Mr. Ramsinghani was
Senior Vice President Commercial Operations and Strategic Planning
at Alastin, where he built the commercial operations infrastructure
to support the organization’s high growth. He was also involved in
assessing and implementing partnerships, international expansion
planning, and corporate strategy projects. Prior to that, he led
the commercial operations group at Kythera Biopharmaceuticals
(acquired by Allergan) in advance of the KYBELLA® launch.
Earlier in his career, Mr. Ramsinghani was an Associate Principal
with ZS Associates, a global management consulting firm
specializing in healthcare sales and marketing strategy, where he
managed multiple client relationships and project teams. While at
ZS Associates, he supported his healthcare clients to launch or
improve performance of their products. Mr. Ramsinghani received his
B.S. in Chemical Engineering from the University of Arizona and his
M.B.A. (with distinction) from the Kellogg School of Management at
Northwestern University.
About Arcutis - Bioscience,
applied to the skin.Arcutis is a late-stage
biopharmaceutical company focused on
developing and commercializing treatments
for unmet needs in immune-mediated
dermatological diseases and conditions, or
immuno-dermatology. Arcutis exploits recent
innovations in inflammation and
immunology to develop potential best-in-class
therapies against validated biological
targets, leveraging our deep development,
formulation and commercialization expertise
to bring to market novel dermatology
treatments, while maximizing our probability of technical success
and financial resources. Arcutis is currently developing four
novel compounds, including topical roflumilast cream (ARQ-151),
topical roflumilast foam (ARQ-154), ARQ-252, and ARQ-255 for
multiple indications, including psoriasis, atopic dermatitis,
seborrheic dermatitis, eczema, vitiligo, and alopecia areata. For
more information, please visit www.arcutis.com or follow the
Company on LinkedIn.
Investors and Media:Heather Rowe ArmstrongVice
President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024